investig
potenti
synerg
antitumor
efficaci
oncolyt
vaccin
properti
chose
ovalbumin
ideal
tumor
antigen
preclin
proof
concept
enhanc
immunogen
antigen
present
retrovir
viruslik
particl
produc
situ
mvinfect
recombin
mv
reveal
normal
growth
genet
stabil
proper
express
present
antigen
potent
antigenspecif
humor
cellular
immun
found
immun
mvsuscept
ifnar
mice
immun
respons
significantli
inhibit
metastasi
format
increas
therapeut
efficaci
compar
control
mv
respect
novel
vivo
tumor
model
use
syngen
murin
melanoma
cell
data
indic
potenti
mv
trigger
select
tumor
antigenspecif
immun
respons
top
direct
tumor
lysi
enhanc
efficaci
despit
signific
advanc
tumor
therapi
efficaci
classic
therapeut
option
like
surgeri
radio
chemo
antibodytherapi
patient
advanc
stage
solid
tumor
entiti
remain
limit
past
year
novel
treatment
option
develop
prime
immun
system
tumor
cell
erad
amongst
present
tumorassoci
antigen
taa
shown
promis
approach
induc
potent
persist
antigenspecif
tcell
respons
purpos
immunotherapi
aim
break
toler
immun
system
endogen
selfor
even
target
patientspecif
mutant
neoantigen
cancer
vaccin
alreadi
licens
current
clinic
trial
compris
sever
differ
antigen
format
includ
vaccin
target
hpv
antigen
caus
agent
cervic
carcinoma
dendrit
cell
load
antigenspeptid
antigenadjuv
conjug
eg
sipuleuceltproveng
antigenencod
modifi
rna
also
virus
consid
tumorlyt
cancer
therapeut
applic
unmodifi
wildtyp
virus
rare
success
sometim
accompani
signific
diseas
caus
infect
advent
recombin
dna
technolog
allow
ration
develop
virus
tailor
specif
lysi
tumor
cell
call
oncolyt
virus
ov
ov
deriv
least
nine
differ
viru
famili
broadli
enter
earli
advanc
phase
clinic
trial
ov
origin
develop
direct
tumor
cell
lysi
due
inher
cytotox
potenti
contribut
immun
system
treatment
efficaci
seem
ambigu
one
hand
antivir
immun
inhibit
oncolysi
hand
least
ov
trigger
antitumor
immun
respons
led
chang
oncolyt
dogma
local
inflamm
due
releas
pathogenand
dangerassoci
molecular
pattern
pamp
damp
respect
oncolysi
transform
origin
immunesuppress
microenviron
immunestimulatori
one
trigger
antivir
also
antitumor
immun
respons
may
also
act
distant
tumor
site
one
promin
exampl
cancer
immunotherapi
oncolyt
ov
talimogen
laherparepvec
tvec
imlyg
genet
modifi
herp
simplex
viru
express
gmcsf
recent
licens
treatment
melanoma
also
gmcsf
encod
recombin
vaccin
strainderiv
measl
virus
mv
preclin
test
markergen
encod
mv
current
develop
sever
phase
two
phase
ii
clinic
trial
wwwclinicaltrialsgov
nevertheless
coexpress
immunestimul
significantli
enhanc
efficaci
mous
tumor
model
although
indic
potenti
benefit
immunestimul
natur
select
tumor
antigen
induc
immun
direct
present
understood
impli
risk
induct
autoimmun
pathogen
select
antigen
also
express
healthi
tissu
especi
combin
immunooncolog
agent
checkpoint
inhibitor
better
focu
induc
antitumor
respons
ov
ie
vesicular
stomat
viru
vsv
maraba
viru
equip
express
cassett
encod
select
taa
direct
immun
howev
desir
respons
could
induc
employ
heterolog
primeboost
scheme
use
adenovir
vector
prime
yet
sinc
otherwis
antiov
immun
seem
domin
parallel
recombin
mv
develop
vaccin
platform
encod
foreign
antigen
extra
express
cassett
call
addit
transcript
unit
atu
mv
express
antigen
rang
differ
pathogen
gener
shown
protect
preclin
model
well
safeti
immunogen
phase
clinic
trial
aim
combin
oncolyt
excel
vaccin
platform
properti
vaccin
strainderiv
mv
ideal
taa
induc
potent
antitumor
immun
respons
immunopathogen
oncofet
tight
junction
molecul
claudin
constitut
taa
anticanc
immunotherapi
physiolog
express
sole
restrict
earli
stage
embryogenesi
placenta
virtual
absent
normal
tissu
due
transcript
silenc
adult
healthi
tissu
aberrantli
frequent
express
variou
type
cancer
high
medic
need
ovarian
lung
gastric
breast
prostat
pediatr
cancer
safeti
promis
anticanc
immunotherapi
target
suggest
clinic
phase
iii
trial
use
monoclon
antibodi
advanc
ovarian
carcinoma
patient
recombin
mv
chosen
oncolyt
platform
choic
sinc
mv
one
platform
well
progress
clinic
trial
note
also
ovarian
carcinoma
target
entiti
vaccin
outlin
studi
mv
shown
excel
safeti
profil
applic
infecti
particl
termin
cancer
patient
therebi
first
evid
clinic
efficaci
gener
moreov
mv
backbon
use
ident
measl
vaccin
strain
extrem
safe
without
caus
latenc
immunogen
therebi
induc
longlast
immun
contrast
eg
poxvir
vector
boostabl
potenti
applic
vaccin
platform
frontrunn
target
chikungunya
viru
zika
viru
also
progress
clinic
develop
enter
phase
ii
specif
profil
dual
applic
oncolyt
viru
well
vaccin
platform
thu
mandat
investig
potenti
synerg
properti
one
candid
increas
chanc
induc
antitumor
immun
taa
without
need
heterolog
primeboost
choos
enhanc
taa
immunogen
optim
present
one
format
highli
immunogen
antigenpresent
viruslik
particl
vlp
vlp
deriv
virus
infecti
vlp
incorpor
present
select
antigen
choic
surfac
exampl
hepat
b
viru
core
antigen
hbcag
base
vlp
present
immunogen
peptid
taa
claudin
isoform
murin
leukemia
viru
mlv
deriv
vlp
present
immunogen
peptid
amyloid
beta
protein
abl
effect
break
immun
toler
autoantigen
therefor
chose
test
taapresent
gagvlp
addit
immunogen
stimulu
sinc
oncolyt
viru
shown
induct
antigenspecif
antitumor
immun
without
heterolog
prime
yet
encod
taa
studi
recombin
mv
gener
express
alon
combin
mlv
gag
suffici
gener
retrovir
vlp
gagexpress
cell
fig
initi
proof
concept
chicken
ovalbumin
ova
chosen
facilit
assess
immun
reaction
trigger
mv
present
antigen
membran
infect
cell
mlvvlp
recombin
mv
encod
membranebound
version
ova
disova
murin
without
mlvgag
gener
character
vitro
recombin
virus
express
respect
antigen
either
cellor
vlpassoci
replic
unmodifi
vaccin
efficaci
mvsuscept
mice
modifi
mv
trigger
signific
cellular
humor
immun
respons
either
ova
autolog
antitumor
immun
inhibit
metastasi
format
also
effect
preestablish
solid
tumor
melanoma
model
demonstr
therapeut
efficaci
new
approach
advanc
vivo
tumor
model
allow
first
time
direct
interact
oncolyt
mv
immun
cell
expect
also
human
system
gener
character
recombin
mv
encod
differ
form
ovaantigen
chosen
sinc
especi
cellular
immunerespons
respect
immunedomin
peptid
mice
use
studi
well
known
thu
consider
support
character
respons
purpos
ova
genet
fuse
transmembran
domain
plateletderiv
growth
factor
receptor
pdgfrtm
give
rise
membranebound
extracellular
variant
disova
readili
incorpor
retrovir
particl
fig
recombin
mv
mv
gagdisova
encod
disova
addit
transcript
unit
atu
follow
p
gene
combin
second
mlv
gagencod
transgen
cassett
front
viral
n
gene
give
rise
situ
produc
vlp
also
gener
fig
analyz
immunogen
particleassoci
antigen
present
result
ovavlp
comparison
exclus
surfac
antigen
express
variant
carri
disova
mv
disova
well
recombin
mv
encod
mlvgag
mv
gag
releas
bare
vlp
gener
fig
recombin
virus
success
rescu
amplifi
passag
vero
cell
compar
titer
tcid
ml
stabil
ova
gag
gene
cassett
addit
introduc
viral
genom
confirm
sequenc
data
shown
express
disova
also
verifi
virus
antigenexpress
clearli
detect
vero
cell
infect
either
mv
disova
mv
gagdisova
stabl
sever
passag
fig
moreov
electron
microscopi
combin
immunogoldlabel
ova
reveal
incorpor
disova
retrovir
vlp
isol
supernat
mv
gagdisova
infect
cell
ova
detect
vlp
isol
supernat
mv
gag
infect
cell
expect
fig
assess
replic
effici
differ
vector
multistep
growth
kinet
cellassoci
releas
viru
perform
follow
infect
low
moi
fig
compar
gfpencod
control
viru
mv
gfp
mv
encompass
disova
transgen
cassett
togeth
without
mlv
gag
grew
similar
kinet
reach
similar
maximum
titer
control
viru
thu
clone
rescu
mvsderiv
vector
result
express
insert
antigen
infect
cell
without
impact
viral
replic
genet
stabil
antigenspecif
cellular
immun
vector
transgen
induc
ovapres
mv
analyz
induct
vectoror
ovaspecif
cellular
immun
respons
splenocyt
ifnar
mice
vaccin
mv
disova
mv
gagdisova
control
mv
atu
empti
vaccin
mv
gag
present
nake
retrovir
particl
primeboost
protocol
fig
isol
analyz
vectorand
antigenspecif
secret
elispot
assay
isol
splenocyt
stimul
mv
bulk
antigen
detect
vectorspecif
tcell
respons
mhci
restrict
siinfekl
sin
ovapeptid
detect
specif
tcell
respons
mhcii
restrict
isqavhaahaeineagr
isq
ovapeptid
detect
specif
tcell
respons
concanavalin
cona
control
gener
tcell
reactiv
splenocyt
mice
reveal
similar
basic
reactiv
broad
tcell
stimul
cona
shown
high
number
secret
cell
secret
cell
per
splenocyt
fig
assess
antivector
cellular
immun
use
mv
bulk
antigen
stimulu
reveal
robust
induct
secret
cell
irrespect
addit
encod
antigen
particl
thu
impact
gener
vectorspecif
tcell
reactiv
associ
differ
vaccin
candid
elispot
assay
use
splenocyt
anim
vaccin
membranebound
disovaencod
mv
without
mlvgag
reveal
approxim
secret
cell
per
splenocyt
specif
restimul
siinfekl
peptid
sin
contrast
control
mice
vaccin
mv
atu
mv
gag
reveal
background
respons
around
produc
cell
per
splenocyt
compar
nonstimul
splenocyt
mock
note
ovaspecif
restimul
isq
trigger
statist
signific
result
around
secret
cell
per
splenocyt
splenocyt
mice
immun
mv
present
disova
surfac
situ
produc
particl
fig
data
argu
robust
induct
antigenspecif
cytotox
tcell
respons
mv
encod
immunogen
antigen
gener
wherea
helper
cell
restimul
isq
peptid
significantli
induc
particleassoci
antigen
expect
antigenspecif
humor
immun
vector
transgen
induc
ovapres
mv
elucid
extent
humor
immun
respons
mice
immun
describ
use
determin
antibodi
preval
serum
first
induct
neutral
antibodi
mv
analyz
fig
group
immun
recombin
mv
develop
mean
viru
neutral
titer
vnt
alreadi
first
immun
fig
middl
panel
mean
titer
increas
second
immun
fig
right
panel
differ
individu
candid
vaccin
becam
evid
assess
induct
ovaspecif
humor
immun
respons
antibodi
bind
ova
quantifi
indirect
elisa
fig
ovaspecif
antibodi
found
alreadi
first
immun
fig
middl
panel
significantli
increas
titer
control
group
vaccin
encod
particleassoci
antigen
variant
disovaencod
mv
reach
mean
antibodi
concentr
day
booster
vaccin
summari
mvderiv
model
vaccin
express
ova
either
infect
cell
alon
combin
present
situ
gener
retrovir
vlp
induc
strong
ovaspecif
cellular
humor
immun
respons
ova
next
assess
immunogen
prototyp
mvderiv
tumor
vaccin
encod
autolog
taa
describ
taa
fig
typic
fourtransmembran
protein
chosen
preclin
proof
concept
fulfil
criteria
ideal
tumor
vaccin
antigen
murin
gene
homologu
use
fulli
mimic
autoantigen
situat
fulllength
gene
fig
insert
atu
follow
p
gene
cassett
respect
vector
plasmid
yield
mv
mv
fig
viru
rescu
individu
viru
clone
gener
character
vitro
describ
disovaencod
virus
virus
easili
amplifi
titer
tcid
ml
reveal
stabl
viru
genom
includ
addit
introduc
cassett
confirm
via
sequenc
data
shown
moreov
express
demonstr
western
blot
analysi
viru
compar
express
cell
infect
vaccin
fig
reveal
consider
specif
stain
therebi
demonstr
effici
incorpor
present
mlvvlp
contrast
stain
found
nake
vlp
express
cell
infect
mv
gag
express
antigen
demonstr
specif
stain
fig
data
solidifi
immunoblot
analysi
vlpcontain
supernat
fraction
densiti
stepgradi
centrifug
reveal
copurif
consider
amount
fraction
data
shown
assess
murin
express
impact
respect
mv
replic
viru
growth
analyz
day
follow
infect
low
moi
purpos
mv
encod
ie
mv
mv
analyz
parallel
gfpencod
mv
gfp
control
viru
cellassoci
viru
titer
fig
well
infecti
viru
releas
supernat
fig
viru
growth
mv
compar
mv
gfp
wherea
mv
delay
approx
h
growth
final
reach
maximum
titer
compar
mv
mv
gfp
control
viru
thu
clone
rescu
mv
express
present
particl
success
recombin
mv
express
insert
antigen
without
critic
impact
viral
replic
reveal
genet
stabil
moreov
incorpor
retrovir
vlp
also
demonstr
therefor
recombin
mv
encod
regard
potenti
candid
oncolyt
immunotherapi
tumorassoci
antigenspecif
cellular
immun
induc
mv
analyz
induct
cellular
immun
respons
splenocyt
anim
vaccin
mv
mv
mv
gag
control
viru
analyz
antigenspecif
secret
elispot
assay
purpos
mice
immun
describ
ovaencod
model
vaccin
fig
splenocyt
analyz
elispot
splenocyt
anim
vaccin
mv
reveal
approx
secret
cell
per
splenocyt
restimul
overlap
peptid
signific
albeit
moder
induct
immun
cell
indic
break
immun
toler
recombin
mv
splenocyt
anim
vaccin
mv
reveal
secret
cell
per
splenocyt
slightli
background
secret
cell
reveal
unspecif
control
stimul
splenocyt
mice
immun
mv
gag
basic
tcell
reactiv
impair
immun
shown
stimul
mv
bulk
antigen
cona
treatment
fig
tumorassoci
antigenspecif
humor
immun
induc
mv
assess
antigenspecif
humor
immun
respons
sera
immun
mice
first
test
antivector
immun
analyz
preval
antimv
neutral
antibodi
mice
immun
recombin
mv
develop
similar
vnt
alreadi
first
immun
boost
second
immun
data
demonstr
success
vaccin
anim
respect
mvderiv
vaccin
candid
fig
determin
induct
humor
immun
respons
antibodi
sera
vaccin
mice
analyz
flow
cytometri
purpos
syngen
murin
cell
endogen
express
surfac
incub
individu
sera
immun
mice
bound
serum
antibodi
detect
flow
cytometri
use
secondari
antibodi
direct
murin
igg
mark
control
virus
mv
atu
mv
gag
induc
antibodi
bound
cell
demonstr
specif
assay
fig
e
contrast
mice
immun
mv
present
surfac
situ
produc
vlp
mv
mv
reveal
signific
induct
antibodi
immun
mice
use
primeboost
protocol
consider
boost
antibodi
respons
second
immun
fig
e
given
high
sequenc
homolog
humor
immun
reactiv
immun
mice
cell
assess
check
crossreact
reactiv
may
therapeut
issu
caus
offtarget
sideeffect
therapi
tissu
inner
ear
therefor
flow
cytometr
analysi
analog
appli
detect
antibodi
perform
sera
mice
immun
mv
mv
atu
mv
mv
gag
use
stain
cell
stabli
express
human
homolog
murin
murin
human
antibodi
observ
sera
experiment
group
except
weak
reactiv
one
mous
immun
mv
supplementari
figur
summari
mvderiv
tumorvaccin
abl
induc
immun
endogen
taa
moder
cellular
respons
predominantli
observ
mice
immun
mv
present
integr
membran
protein
infect
cell
humor
immun
respons
induc
vaccin
mv
present
surfac
situ
produc
vlp
well
mv
express
membranebound
vaccinationinduc
serum
antibodi
analyz
upon
capabl
forc
target
cellspecif
lysi
fcmediat
immun
effector
mechan
complementdepend
cytotox
cdc
xttbase
vitro
assay
use
cell
perform
targetspecif
kill
cell
analyz
compar
recombin
monoclon
antibodi
posit
control
latter
reveal
remark
potenti
antibodi
provok
fcmediat
cytotox
fig
inde
sera
mice
vaccin
mv
show
targetspecif
cdc
lytic
activ
fig
also
sera
mv
mice
induc
fcmediat
lysi
cell
reveal
somewhat
weaker
lysi
well
one
nonrespond
among
anim
thu
antibodi
induc
mvderiv
vaccin
encod
taa
elicit
autoantibodi
kill
taaexpress
cell
cdc
therebi
target
antigenposit
tumor
cell
potenti
effector
mechan
interestingli
antibodi
function
becam
signific
sera
induc
immun
mv
encod
particleassoci
taa
potenc
antibodi
respons
induc
immun
recombin
mv
mv
investig
highli
aggress
lung
metastasi
model
purpos
cell
clone
stabli
express
mv
vaccin
strain
receptor
suscept
mv
oncolysi
immunotherapi
target
gener
transduct
lentivir
vector
encod
respect
transgen
express
protein
reveal
via
flow
cytometri
use
well
antibodi
figur
singl
cell
clone
express
protein
high
amount
inocul
sc
flank
syngen
ifnar
mice
effect
tumor
growth
monitor
tumor
resect
stabl
express
vivo
passag
demonstr
supplementari
figur
protect
studi
ifnar
mice
immun
twice
mv
mv
mv
gag
vector
control
medium
alon
mock
day
second
immun
mice
challeng
iv
cell
clone
form
lung
metastas
fig
quantifi
ex
vivo
day
challeng
fig
macroscop
analysi
lung
mice
vaccin
mv
reveal
significantli
reduc
number
metastas
compar
mv
gag
immun
mocktreat
mice
fig
b
note
mice
mv
group
free
metastat
nodul
lung
group
robust
tumor
growth
evid
anim
total
n
mv
immun
mice
reveal
somewhat
reduc
count
metastat
nodul
lung
howev
statist
signific
mock
viru
control
fig
conclus
data
show
prophylact
vaccin
mv
strongli
inhibit
even
protect
mice
highli
aggress
cell
form
lung
metastasi
iv
applic
tumor
cell
mimick
pulmonari
spread
via
hematogen
rout
final
therapeut
efficaci
oncolyt
mv
addit
encod
taa
mv
mv
assess
direct
comparison
efficaci
mv
includ
potenti
unspecif
immunostimulatori
effect
result
releas
vlp
mv
gag
larg
immunocompet
model
preestablish
tumor
purpos
cell
select
clone
inocul
sc
flank
ifnar
mice
tumor
reach
size
approx
mm
treatment
start
inject
tcid
mv
mv
mv
gag
control
viru
consecut
day
fourth
cohort
treat
inject
similar
volum
medium
without
therapeut
substanc
treatment
control
mock
tumor
control
group
grew
aggress
mice
sacrif
day
initi
treatment
fig
growth
tumor
significantli
inhibit
cohort
treat
mv
gag
fig
result
significantli
longer
surviv
mice
fig
cohort
treat
mv
mv
experienc
even
stronger
delay
tumor
growth
fig
increas
median
surviv
vs
day
post
initi
treatment
enhanc
therapeut
efficaci
antigenencod
mv
statist
signific
comparison
mv
gag
encod
specif
tumor
antigen
even
take
account
mous
mv
gag
cohort
prematur
die
day
reveal
benefici
effect
addit
equip
oncolyt
mv
antitumor
vaccin
compon
aim
cancer
immunotherapi
induct
power
persist
antitumor
immun
stimul
virus
also
develop
cancer
treatment
option
call
oncolyt
virus
gener
immunogen
oncolyt
mv
gener
encod
model
antigen
ova
ideal
figur
effector
function
humor
immun
posit
control
cdc
mab
use
indic
concentr
parallel
irrelev
serum
without
antibodi
test
kill
cdc
assay
use
xtt
substrat
stabli
transfect
human
isoform
serv
target
cell
human
serum
sourc
complement
factor
analyz
cdcmediat
lytic
activ
percentag
cell
lysi
indic
refer
complet
lyse
cell
b
autoantibodi
mediat
cell
kill
stabli
transfect
human
isoform
incub
sera
immun
mice
test
cdc
statist
differ
group
assess
twoway
anova
tukey
test
p
p
taa
express
either
membranebound
addit
present
surfac
situ
produc
vlp
recombin
virus
stabli
express
desir
antigen
vlp
cellular
consider
humor
antitaa
immun
respons
induc
use
model
antigen
ova
allow
determin
respons
major
tcell
respons
induc
system
also
discrimin
tcell
respons
induc
cellor
vlppresent
antigen
taaencod
mv
significantli
efficaci
treat
preestablish
highli
aggress
tumor
control
oncolyt
mv
furthermor
also
significantli
inhibit
metastasi
format
prophylact
mous
tumor
model
result
confirm
initi
hypothesi
recombin
measl
viru
design
use
virotherapi
equip
immunotherapeut
purpos
therebi
significantli
enhanc
immunotherapeut
mode
action
mv
oncolyt
therapi
analyz
immunotherapeut
effect
least
partial
immunocompet
anim
model
necessari
mvdriven
virotherapi
larg
hamper
resist
mice
murin
cell
mv
infect
alreadi
level
cell
entri
sinc
murin
mv
receptor
homologu
less
well
recogn
viru
therefor
mvbase
virotherapi
larg
analyz
immunodefici
mice
bear
human
xenograft
tumor
analyz
oncolyt
mv
immunocompet
mous
tumor
model
entri
restrict
partial
overcom
use
retarget
mv
targettransgen
murin
tumor
cell
line
system
howev
allow
direct
natur
interact
replic
mv
immun
cell
due
lack
respect
mv
receptor
murin
immun
cell
studi
develop
first
time
larg
immunocompet
albeit
somewhat
impair
mvsuscept
tumorbear
mous
model
allow
assess
direct
indirect
interact
replic
mv
vector
compon
immun
system
vivo
model
may
therefor
predict
immunemedi
effect
although
lack
typei
ifndriven
immunestimulatori
program
compris
power
stimulu
adapt
immun
viru
infect
human
patient
limit
sever
sinc
mv
primat
viru
man
natur
host
therefor
virushost
adapt
grant
tumor
cell
known
often
upregul
vaccinestrain
receptor
protect
complement
activ
sinc
major
complement
regul
protein
mcp
nevertheless
individu
patient
tumor
stratifi
treatment
sinc
least
oncolyt
vaccin
match
tumor
antigen
profil
suscept
primari
tumor
cell
measl
viru
infect
like
quit
advantag
boost
lytic
mode
action
oncolyt
vaccin
addit
encod
taa
present
either
surfac
infect
cell
situ
produc
vlp
cellular
strong
humor
antitaa
immun
respons
induc
use
mvderiv
platform
note
humor
immun
becam
signific
everi
time
vlppresent
vaccin
use
observ
may
defin
detail
futur
experi
even
remark
sinc
immun
respons
induc
background
lack
proper
stimul
adapt
respons
typei
ifn
pathway
like
also
import
gain
full
antitumor
potenc
upon
cancer
vaccin
especi
sinc
iggtyp
cdc
effector
function
mice
predominantli
becam
induc
known
typic
associ
respons
therefor
model
may
underestim
potenc
vaccin
compon
nevertheless
tumorspecif
respons
substanti
enhanc
treatment
efficaci
preestablish
highli
aggress
tumor
significantli
inhibit
metastasi
format
importantli
tumor
vaccin
properti
independ
heterolog
primeboost
protocol
tumor
antigen
demonstr
necessari
vsvor
maraba
virusencod
tumor
antigen
antitaa
immun
like
limit
immunodomin
viral
antigen
altern
heterolog
primeboost
cotransf
tumor
antigenspecif
tcell
express
cdna
librari
reveal
efficaci
obvious
need
appli
mvbase
vector
despit
signific
immun
respons
also
mv
platform
therebi
onecompon
mvbase
oncolyt
immunotherapeut
could
introduc
much
easier
clinic
trial
protocol
mv
vsv
clinic
develop
virotherapeut
purpos
differ
tumor
entiti
includ
ovarian
carcinoma
also
reveal
signific
upregul
thu
constitut
ideal
tumor
vaccin
target
sinc
autoimmun
anticip
inde
passiv
immunotherapi
mab
current
clinic
develop
patient
recurr
advanc
ovarian
cancer
antibodi
effect
induc
respons
cdc
antibodydepend
cellular
cytotox
adcc
opson
tumor
cell
observ
effici
kill
targetposit
cell
cdc
use
vaccineinduc
antibodi
mous
sera
robustli
induc
use
vlpencod
vaccin
advantag
use
oncolyt
vaccin
induc
humor
antitumor
immun
compar
applic
respect
mab
may
twofold
firstli
oncolyt
vaccin
possess
addit
mode
action
directli
lyse
tumor
cell
viru
replic
secondli
oncolyt
vaccin
induc
polyclon
antibodi
therebi
impair
resist
develop
tumor
cell
harbor
mutat
singl
epitop
target
given
mab
reveal
signific
compar
respect
control
group
experi
group
treat
mv
data
strengthen
initi
hypothesi
vlp
present
enhanc
humor
immun
respons
despit
preval
immun
toler
observ
sole
applic
hbcagbas
vlp
mlvderiv
vlp
interestingli
experi
use
vaccin
encod
disova
model
antigen
may
indic
mechanist
background
vlpencod
vaccin
induct
helper
cell
becam
signific
tcell
help
requir
effici
induct
humor
immun
respons
may
thu
explain
high
capac
mv
induc
humor
respons
note
addit
express
taa
turn
suffici
induc
potent
antitumor
immun
respons
differ
previous
studi
altern
oncolyt
vaccin
platform
need
heterolog
prime
induct
antitumor
respons
interestingli
antibodi
effector
function
well
protect
prophylact
set
becam
signific
use
vlppresent
antigen
qualiti
might
relat
induc
facilit
antibodi
class
switch
anyway
data
provid
evid
target
immun
induct
effect
viru
replic
alon
alreadi
act
releas
stimulatori
dangerand
pathogenassoci
motif
pattern
damp
pamp
respect
tumor
cell
lysi
moreov
oncolyt
virus
known
addit
stimul
antitumor
immun
direct
indirect
interact
via
infect
tumor
cell
immun
cell
hold
especi
true
mv
natur
lymphotrop
viru
also
vaccin
strain
virus
reveal
strong
prefer
dendrit
cell
macrophag
vivo
moreov
stimulatori
action
infect
alreadi
shown
properti
virus
allow
tumor
vaccin
activ
also
prophylact
set
mice
without
tumor
posit
impact
enhanc
immunotherapeut
mode
action
also
demonstr
preclin
model
test
recombin
mv
encod
gmcsf
gener
immun
stimulu
checkpoint
inhibitor
antibodi
gmcsfencod
mv
mimic
talimogen
laherparepvec
tvec
imlyg
tm
first
oncolyt
viru
approv
treatment
malign
melanoma
base
success
phase
iii
optim
trial
therapeut
efficaci
ov
close
link
induct
antitumor
immun
respons
current
combin
tvec
checkpoint
inhibitor
clinic
trial
explor
potenti
synerg
inflammatori
oncolyt
virotherapi
inhibit
either
axi
releas
impair
tumorinfiltr
tcell
treatment
patient
mab
reveal
high
antitumor
efficaci
gener
releas
tcell
blockad
immunotherapi
also
risk
offtarget
effect
treat
patient
develop
highgrad
immunerel
advers
event
summari
studi
provid
proof
concept
approach
present
tumorassoci
antigen
especi
particl
oncolyt
vaccinestrain
deriv
mv
tumor
vaccineplatform
mv
vaccin
strain
use
test
preclin
clinic
platform
gener
vaccin
least
differ
pathogen
oncolyt
efficaci
analys
least
clinic
phase
ii
trial
recombin
vaccin
provid
power
protect
immun
respons
appropri
anim
model
clinic
test
studi
first
evid
provid
mv
platform
combin
oncolyt
tumor
vaccin
approach
even
strong
enough
break
toler
endogen
tumor
antigen
thu
use
gener
potent
tumor
vaccin
potent
highli
specif
antitumor
immun
respons
significantli
enhanc
therapeut
efficaci
novel
meaning
vivo
model
solid
tumor
growth
metastasi
format
use
clinic
relev
tumor
antigen
thu
oncolyt
mv
present
select
taa
may
improv
virotherapi
efficaci
increas
immunotherapeut
aspect
approach
cell
vero
atcc
atcc
atcc
atcc
atcc
cell
line
purchas
atcc
manassa
va
usa
cultur
describ
longer
month
thaw
origin
stock
transgen
cell
cultur
glutamax
fb
hygromycin
b
mgml
invitrogen
puromycin
invivogen
toulous
franc
cell
cultur
glutamax
supplement
fb
hygromycin
b
mgml
blasticidin
respect
plasmid
murin
gene
synthes
geneart
regensburg
germani
insert
invitrogen
yield
use
amplifi
ova
open
read
frame
orf
pcr
flank
mluiaatii
site
sequenc
clone
yield
obtain
membraneassoci
ovalbumin
ova
amplifi
pcr
without
stop
flank
bgliisacii
site
sequenc
clone
yield
ova
fragment
introduc
via
bgliisacii
pdismod
encod
pdgfrtm
pdismod
modif
pdisplay
invitrogen
mlui
aatii
site
sp
pdgfrtmsequenc
respect
disova
insert
p
mv
atu
p
via
aatiimlui
yield
p
mv
p
p
mv
disova
p
respect
cmv
promot
cassett
insert
via
notisbfi
gener
p
poliimv
p
p
poliimv
disova
p
gener
genom
vlpencod
mv
murin
leukemia
viru
mlv
gag
gene
amplifi
equip
flank
mluiaatii
site
pcr
clone
p
mv
gfp
deriv
pb
atu
encod
gfp
pren
yield
p
mv
mlvgag
n
p
poliimv
mlvgag
n
construct
insert
promot
cassett
p
poliimv
merss
h
p
mv
mlvgag
n
via
psri
fragment
cmv
promot
gag
gene
cassett
transfer
via
notisbfi
p
mv
p
p
mv
pdisova
p
obtain
p
poliimv
mlvgag
n
p
p
poliimv
mlvgag
n
disova
p
respect
detail
primer
pcr
protocol
avail
upon
request
lentivir
transfer
vector
encod
control
promot
gener
shuttl
orf
togeth
promot
cassett
use
gateway
clone
invitrogen
use
convent
clone
techniqu
vector
modifi
encod
fusion
protein
downstream
hpgl
promot
yield
likewis
pcramplifi
orf
clone
togeth
irespuro
r
cassett
psew
yield
product
lentivir
vector
lentivir
vector
lv
produc
titer
via
flow
cytometri
cell
use
third
gener
lv
vector
system
transfer
vector
plasmid
wide
establish
protocol
describ
stabl
coexpress
target
cell
transduc
use
lv
vectormedi
gene
transfer
subsequ
select
encod
antibiot
resist
singl
cell
clone
separ
clone
ring
screen
via
flow
cytometri
cell
gener
lvmediat
gene
transfer
transduc
cell
select
hygromycin
b
mgml
invitrogen
virus
sequenc
analysi
thereof
recombin
mv
rescu
passag
passag
describ
store
titer
determin
tcid
titrat
accord
method
kaerber
spaerman
rna
genom
recombin
mv
analyz
describ
western
blot
analysi
vero
cell
cultur
lyse
two
day
post
infect
moi
immunoblot
previous
describ
polyclon
antibodi
reactiv
fulllength
ibl
co
ltd
gunma
japan
use
primari
antibodi
rabbit
antiovalbumin
polyclon
antibodi
novu
biolog
co
usa
rabbit
antimvn
polyclon
antibodi
abcam
cambridg
uk
mvn
goat
leukemia
viru
rlv
antibodi
atcc
hrpcoupl
donkey
antirabbit
igg
h
l
polyclon
antibodi
rockland
gilbertsvil
pa
hrpcoupl
rabbit
antigoat
polyclon
antibodi
dako
glostrup
denmark
serv
secondari
antibodi
appropri
immunoelectron
microscop
analysi
viruslik
particl
vlp
vlp
produc
infect
vero
cell
respect
mv
h
supernat
infect
cultur
clear
centrifug
rpm
min
filtrat
vlp
pellet
g
h
fix
pb
paraformaldehyd
vlp
prepar
analys
immunoelectron
microscopi
describ
use
monoclon
antibodi
ganym
pharmaceut
ag
mainz
germani
pool
sera
ovavaccin
mice
paulehrlichinstitut
langen
germani
anim
experi
anim
experi
carri
complianc
regul
german
anim
protect
law
author
rp
darmstadt
sixto
ifnar
mice
inocul
intraperiton
tcid
viru
control
day
parallel
take
serum
sampl
splenocyt
sera
prepar
euthan
day
intraven
tumorchalleng
immun
mice
challeng
day
inject
cell
euthan
challeng
lung
prepar
fix
bleach
simultan
feket
solut
tumor
treatment
mice
inocul
cell
right
flank
treat
describ
tumor
growth
close
monitor
mice
sacrif
tumor
reach
volum
mm
antibodi
elisa
ovaspecif
igg
antibodi
titer
determin
describ
follow
modif
unspecif
bind
block
use
caseinbas
block
buffer
sigmaaldrich
sera
test
predilut
block
buffer
hrpconjug
secondari
goat
antimous
igg
antibodi
jackson
immunoresearch
newmarket
uk
use
detect
nonlinear
regress
analysi
curv
fit
standard
curv
gener
use
antiovalbumin
mab
sigmaaldrich
serial
dilut
igg
concentr
sampl
calcul
valu
use
graphpad
prism
fac
bind
assay
antibodi
bind
nativ
epitop
analyz
fac
describ
cell
target
nonpurifi
serum
sampl
goatantimous
igg
secondari
antibodi
jackson
immunoresearch
use
stain
use
facscantoii
equip
bd
bioscienc
heidelberg
germani
neutral
assay
viru
neutral
titer
vnt
determin
describ
elispot
assay
murin
elispot
assay
perform
describ
use
per
peptid
overlap
peptid
mix
jpt
peptid
technolog
gmbh
berlin
germani
restimul
tcell
specif
reactiv
control
use
isqpeptid
stimul
well
mani
spot
separ
set
spot
maximum
spot
count
reliabl
determin
cdcassay
cell
plate
plate
incub
dilut
sera
immun
anim
activ
human
serum
complement
sourc
triplic
min
control
well
maximum
lysi
achiev
vv
triton
pb
lytic
activ
measur
use
xtt
substrat
accord
manufactur
instruct
cell
prolifer
kit
ii
xtt
roch
mannheim
germani
calcul
follow
specif
lysi
l
exp
l
max
l
min
l
max
l
exp
absorb
sampl
nm
l
max
absorb
control
l
min
absorb
medium
control
immunohistochemistri
ihc
ihc
analysi
describ
previous
tissu
section
xenograft
tumor
use
primari
rabbit
antiserum
ibl
hamburg
de
antibodi
ngml
abcam
cambridg
uk
follow
incub
powervis
polym
hrpconjug
antirabbit
secondari
antibodi
immunolog
duiven
nl
statist
analysi
statist
analysi
perform
graphpad
prism
softwar
graphpad
softwar
inc
la
jolla
ca
signific
differ
group
assess
use
oneway
anova
nonparametr
mannwhitney
u
test
twoway
anova
tukey
posttest
specifi
respect
figur
legend
data
avail
dataset
gener
andor
analys
current
studi
avail
correspond
author
reason
request
